Zepp Health Earnings Presentation 4Q25 Financial and Operating Results 01 06 4Q25 Revenue and Gross Margin Trend 07 Adjusted Operating Expenses 10 2 Empowering Health, Inspiring Joy Fourth Quarter and Full Year 2025 Investor Relations 15 March 2026 Table of Contents 02 FY25 Financial and Operating Results 03 Revenue 04 4Q25 Gross Margin 05 Business Outlook FY25 Gross Margin 08 Net Income/ Earnings Performance Liquidity Position 09 4Q25 Financial and Operating Results $85.2 Million Revenue -$6.4 Million Adju ...

Ajinomoto (OTCPK:AJIN.Y) 2026 Investor Day March 15, 2026 08:00 PM ET Company ParticipantsKaori Ono - Executive Officer in Charge of SustainabilityShigeo Nakamura - President and CEOTakashi Miyazaki - VP of Equity ResearchYusuke Iimura - Investor Relations ManagerConference Call ParticipantsHiroki Watanabe - Senior AnalystManabu Sumoge - Senior AnalystMina Yano - Senior AnalystRei Ihara - Senior AnalystYusuke IimuraGood morning, everyone. Thank you very much for taking precious time out of your busy schedul ...

Genscript Biotech (SEHK:01548) H2 2025 Earnings call March 15, 2026 07:15 PM ET Company ParticipantsAixi Bai - General ManagerAllen Guo - CEOPhil Zhou - CFORay Chen - President of GenScript Life Science GroupSherry Shao - Rotating CEOYang Huang - Executive DirectorConference Call ParticipantsLaurence Tam - AnalystLinda Xu - AnalystOperatorGood day, thank you for standing by. Welcome to GenScript 2025 annual results conference call. At this time, all participants are in a listen-only mode. After the speaker' ...

Genscript Biotech (SEHK:01548) H2 2025 Earnings call March 15, 2026 07:15 PM ET Company ParticipantsAixi Bai - General ManagerAllen Guo - CEOJosie Zhou - Interim CFOPhil Zhou - CFORay Chen - President of GenScript Life Science GroupSherry Shao - Rotating CEOYang Huang - Executive DirectorConference Call ParticipantsLaurence Tam - AnalystLinda Xu - AnalystOperatorGood day, thank you for standing by. Welcome to GenScript 2025 annual results conference call. At this time, all participants are in a listen-only ...

Financial Performance and Key Metrics - In 2025, the company achieved total revenue of $959.5 million, representing a 61.4% year-over-year increase, with gross profit more than doubling [33][34] - Adjusted net profit reached nearly $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - The adjusted gross profit margin was stable at 51.2%, with adjusted gross profit growing 12.5% year-over-year to $267.3 million [39] Business Segment Performance - The GenScript Life Science Group generated revenue of $522.1 million, growing 14.8% year-over-year, and was identified as the growth engine and profit center [33][38] - ProBio reported total revenue of $388.7 million, with 21% organic growth excluding the LaNova deal, driven by strong customer demand for protein and antibody services [40][41] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Performance - The North American and European markets contributed 38% of total revenue, indicating a notable increase in the company's international footprint [41] - The Asia Pacific region, particularly Greater China, showed increased activity, contributing to the overall growth [10] Company Strategy and Industry Competition - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform leadership, ecosystem expansion, and automation-driven scale [44] - The strategy includes strengthening global partnerships, enhancing customer reach, and integrating new modalities into existing platforms [44] - The company is committed to maintaining its competitive edge through strategic investments in R&D and operational efficiency improvements [54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the CRO and CDMO sectors, citing a rebound in global biopharmaceutical investment and financing [59] - The company anticipates revenue growth for the GenScript Life Science Group to be between 15% and 18% in 2026, with an adjusted gross margin expected to reach 52% [44] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [6] - The company reported a share loss of $310.4 million related to its investment in Legend Biotech, which is expected to improve as Legend's financial position strengthens [34][37] Q&A Session Summary Question: Revenue recognition from LaNova deal - Management confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [48][50] Question: Profitability and gross profit margin decline - Management acknowledged slight fluctuations in gross profit margins due to investments in global expansion and emphasized a focus on cost optimization and operational efficiency to improve profitability [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and improved capacity utilization in China [59][62] Question: Future strategy for Legend Biotech - Management highlighted Legend Biotech's significant progress and profitability, stating that they are not planning to establish new biotech companies but will leverage existing platforms to accelerate drug discovery [64][66] Question: Mitigating customer concerns regarding regulatory scrutiny - Management clarified that the company provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Opening Remarks Shigeo Nakamura Director, Representative Executive Officer, President & Chief Executive Officer March 16, 2026 Today's Message • In the Ajinomoto Group, sustainability initiatives are the core of ASV initiatives. They work as one with our business strategies to create both social and economic value and accelerate business growth. • We will aim to maximize ASV through initiatives that reduce negative impact and expand positive impact, thereby increasing the resilience of our business foundati ...

Investor Presentation Presenter: David Dickson MD/CEO For personal use only March 2026 ASX: LKE; OTC: LLKKF lakeresources.com.au Disclaimers General Statement and Cautionary Statement This presentation has been prepared by Lake Resources N.L. (Lake) for information purposes and not any particular party. The information in this presentation is based upon public information and internally developed data and reflects prevailing conditions and views as of this date, all of which are accordingly subject to chang ...

Vaxart Conference Call Summary Company Overview - **Company**: Vaxart - **Industry**: Biotechnology, specifically focusing on oral vaccine development Key Developments - **Acquisition**: Sanofi acquired Dynavax, Vaxart's partner, in February 2026, which is expected to enhance collaboration on the oral COVID-19 vaccine program [4][6] - **Cash Runway**: Vaxart has a cash runway extending into the second quarter of 2027, allowing for continued operations without immediate need for capital raising [4][20] - **Clinical Trials**: The company is prioritizing the execution of its Phase 2B COVID-19 trial, with expected top-line data from a 400-participant cohort in early Q2 2026 [5][28] Clinical Programs - **COVID-19 Vaccine**: - Collaboration with BARDA for funding the Phase 2B trial [8] - A $50 million milestone payment is contingent upon advancing to Phase 3 after Phase 2B results [9][28] - **Norovirus Program**: - The start of the Phase 2B trial is contingent on securing a strategic partnership or non-dilutive funding [11][12] - Positive results from a study on lactating mothers suggest potential for mucosal immunity transfer to infants [12][41] - **Avian Influenza**: - Completed primary analysis showing 100% protection in a ferret model, with plans to publish results in a peer-reviewed journal [33] Financial Management - **Cost Management**: - Recent lease termination expected to save over $1 million annually [31] - Headcount reduced from 105 in 2024 to 65 in 2025, allowing for consolidation of operations [74] - **Funding Strategy**: - Preference for non-dilutive funding through partnerships, but open to other financing options if necessary [21][50] Market Position and Strategy - **Competitive Advantage**: - Vaxart's oral vaccine platform addresses vaccine fatigue and needle hesitancy, positioning it uniquely in the market [25] - Global demand for effective immunization remains strong, with significant funding from international stakeholders [26] - **Partnership Discussions**: - Ongoing discussions with potential partners for various programs, including avian flu and norovirus [48][46] - Interest in the entire oral vaccine platform beyond traditional licensing [46] Regulatory and Compliance - **FDA Interactions**: - Vaxart maintains operational responsibility for the COVID-19 program until the completion of the Phase 2B trial [8] - The company is working closely with BARDA to finalize data release timelines, which have been delayed from Q1 to early Q2 2026 [17][81] Future Outlook - **Next Steps**: - If COVID-19 trial data is positive, Vaxart will submit a data package to the FDA for potential advancement to Phase 3 [28] - The company is exploring additional funding opportunities and partnerships to support ongoing and future clinical trials [14][16] Additional Insights - **Market Sentiment**: - The domestic vaccine environment is characterized by increased scrutiny, but Vaxart's unique delivery method may help re-engage the market [25] - **Operational Adjustments**: - Consolidation of facilities and reduction in manufacturing footprint to align with strategic goals and cost management [90] This summary encapsulates the key points discussed during the Vaxart conference call, highlighting the company's strategic direction, clinical programs, financial management, and market positioning.

WM Technology, Inc. Q4 & Full Year 2025 Results March 12, 2026 Disclaimer This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to WM Technology, Inc. ("WM", the "Company", "we", "us", "our") and for no other purpose. References in this presentation to the "10- K" refer to the Annual Report on Form 10-K for the period ended December 31, 2025 filed with the Securities and Exchange Commission (the "SEC"). No ...

Summary of Monroe Capital Corporation Special Meeting Company Overview - **Company Name**: Monroe Capital Corporation (MRCC) - **Meeting Date**: March 13, 2026 - **Meeting Type**: Special Meeting of Stockholders Key Points Meeting Proceedings - The meeting was called to order by Mick Solimini, Chief Financial Officer and Chief Investment Officer of MRCC, with a quorum confirmed by Ronald A. Holinsky, Chief Compliance Officer and Corporate Secretary, indicating that 13,677,893 shares were present, representing approximately 63.13% of the voting power of all issued shares [4][5] - The meeting's agenda included two main proposals: the asset sale proposal and the merger proposal, both recommended for approval by the board of directors [5][7] Voting Results - **Asset Sale Proposal**: - 11,645,478 shares voted in favor, which is 53.74% of the outstanding shares entitled to vote [10] - **Merger Proposal**: - 11,636,057 shares voted in favor, which is 53.70% of the outstanding shares entitled to vote [10] - Both proposals received the affirmative vote of a majority of the outstanding shares and were approved [11] Important Notes - The results of the voting will be reported on a Form 8-K to be filed with the SEC within four business days following the meeting [10] - The meeting concluded with appreciation expressed to stockholders for their participation [11] Additional Information - The meeting was conducted virtually, allowing stockholders to vote online [6][8] - The inspector of election, Charles Zaid, was appointed to oversee the voting process and ensure compliance with the meeting's regulations [3]